Nestle and Phospha-E
This article was originally published in The Tan Sheet
Executive Summary
Nestle has exercised its option to finalize a commercial agreement to use Phosphagenics' Phospha-E as an ingredient in medical foods for treatment and prevention of metabolic syndrome, Phosphagenics announces Jan. 18. Nestle will pay the firm an option fee and both firms will begin human trials to "provide science-based evidence" for the ingredient, according to the terms of the agreement. The agreement also requires Nestle to launch a product containing Phospha-E within 12 months of regulatory approval. Phosphagenics will be responsible for manufacture and sales of the ingredient to Nestle. Nestle recently announced plans to expand its Nutritional division with the $2.5 bil. acquisition of Novartis' Medical Nutrition unit (1"The Tan Sheet" Dec. 18, 2006, p. 8)...
You may also be interested in...
Nestle Looks To Cook Up Nutrition Product Sales With Novartis MN Acquisition
Nestle looks to become the number two company in the healthcare nutrition field, including the infant formula market, with its planned $2.5 bil. acquisition of Novartis' Medical Nutrition unit
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.